Two novel Rhodamine-pyrazolone-based colorimetric off-on fluorescent chemosensors for Fe(3+) ions were designed and synthesized using pyrazolone as the recognition moiety and Rhodamine 6G as the signalling moiety. The photophysical properties and Fe(3+) -binding properties of sensors L(1) and L(2) in acetonitrile-aqueous solution were also investigated. Both sensors successfully exhibit a remarkably 'turn-on' response, toward Fe(3+) , which was attributed to 1: 2 complex formation between Fe(3+) and L(1) /L(2) . The fluorescent and colorimetric response to Fe(3+) can be detected by the naked eye, which provides a facile method for the visual detection of Fe(3+) .
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bio.2709 | DOI Listing |
J Pharm Pharmacol
October 2024
Department of Pharmacology, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad 44000, Pakistan.
Objective: The study was aimed at the synthesis and pharmacological investigation of (4Z)-4-(2-hydroxybenzylidine)-5-methyl-2-(pyridine-3-ylcarbonyl)-2, 4-dihydro-3H-pyrazole-3-one (IIc) in mice model of scopolamine-induced neurodegeneration and cognition impairment.
Methods: The behavioural studies included Y-Maze Test, Water Morris Test, and Novel Object Recognition Test in Albino mice (20-25 g). Scopalamine was used as an inducing agent.
Brain Res
June 2024
Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan,China. Electronic address:
Exploring the intricate pathogenesis of Vascular Dementia (VD), there is a noted absence of potent treatments available in the current medical landscape. A new brain-protective medication developed in China, Edaravone dexboeol (EDB), has shown promise due to its antioxidant and anti-inflammatory properties, albeit with a need for additional research to elucidate its role and mechanisms in VD contexts. In a research setup, a VD model was established utilizing Sprague-Dawley (SD) rats, subjected to permanent bilateral typical carotid artery occlusion (2VO).
View Article and Find Full Text PDFExp Aging Res
October 2024
Department of Pharmacology, SVKM's Dr Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Objective: The purpose of the study was to explore Edaravone and Noscapine in anAlCl3-induced Alzheimer's disease (AD) model.
Methods: Morris Water Maze (MWM), Novel Object Recognition (NOR), andY-maze tests with TNF-α, IL-1, IL-6, amyloid-β, CAT, SOD and MDAlevels were performed, followed by brain histology.
Results: On the probe trial, the MWM demonstrated a decrease in escape latencyfollowed by an increase in the target quadrant.
Behav Neurol
July 2023
Zanjan Applied Pharmacology Research Center, Zanjan University of Medical sciences, Zanjan, Iran.
Alzheimer's disease (AD), as the main cause of dementia, has a progressive and neurodegenerative pattern with number of cases increasing over the next decades. Therefore, discovering an effective treatment with the ability to invert memory impairment and pathophysiological events of AD seems to be required. The present study performed to investigate the probable effects of Edaravone (EDV) in AD-like disorder induced by intracerebroventricular streptozotocin (ICV-STZ) administration in mice.
View Article and Find Full Text PDFEur J Pharmacol
July 2023
The Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha Medical University, Changsha, 410000, China; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410000, China. Electronic address:
Introduction: DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment. However, the impacts of NBP and Eda-Dex on poststroke mental deficits are still poorly understood. In this study, we aimed to investigate and compare the influences of NBP and Eda-Dex on neurological function and cognitive behavior in rats with ischemic stroke.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!